Expression of the mucin-associated sialyl-Tn (STn) antigen has been associated with a decreased survival in patients with colorectal, gastric, and ovarian cancer. To better understand the role of STn antigen in tumor biology, we developed STn(+) (called LP) and STn(-) (called LN) clonal cell lines from a parental metastatic rat colon carcinoma cell line (LMCR). Both derivative cell lines exhibited identical proliferation rates in vitro. LP cells strongly expressed STn antigen both in vitro and in vivo, and were poorly tumorigenic when given to syngeneic rats. LN cells did not express STn antigen in vitro, but as in vivo tumors these cells rapidly acquired STn expression, readily formed tumors, and were highly lethal. When rats were given an otherwise lethal inoculum of i.p. LN cells, pre-immunization with synthetic STn antigen conjugated to keyhole limpet hemocyanin (STn-KLH) resulted in a 60% survival rate. When LN cells were injected subcutaneously in the presence of STn-KLH-sensitized lymphocytes, tumor growth was decreased. Distribution of STn antigen in normal organs of host rats is quite similar to that of humans. This model mimics human disease and should facilitate studies of mucin-associated antigens in tumor biology and the development of immunotherapeutic agents based on mucin-related antigens.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1023/a:1022248408857 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Efficient Neutralizing Antibodies Induction by Human Parvovirus B19 Epitope-Presenting Protein Nanoparticles.
Microbiol Immunol
January 2025
Department of Biochemistry and Molecular Biology, Faculty of Agriculture and Life Science, Hirosaki University, Hirosaki, Japan.
Human parvovirus B19 (B19V) causes fetal hydrops in pregnant women. Despite the significant impact of this virus, effective vaccines remain unclear. In this study, we successfully engineered B19V protein nanoparticles by fusing the N-terminal receptor-binding domain corresponding to 5-80 amino acids of VP1 with two distinct types of self-assembling protein nanoparticles.
View Article and Find Full Text PDFDifferential expression of ST6GALNAC1 and ST6GALNAC2 and their clinical relevance to colorectal cancer progression.
PLoS One
September 2024
School of Life and Medical Sciences, University of Hertfordshire, Hatfield, United Kingdom.
Colorectal cancer (CRC) has become a significant global health concern and ranks among the leading causes of morbidity and mortality worldwide. Due to its malignant nature, current immunotherapeutic treatments are used to tackle this issue. However, not all patients respond positively to treatment, thereby limiting clinical effectiveness and requiring the identification of novel therapeutic targets to optimise current strategies.
View Article and Find Full Text PDFSialyl-Tn glycan epitope as a target for pancreatic cancer therapies.
Front Oncol
September 2024
Instituto de Investigação e Inovação em Saúde (i3S), Universidade do Porto, Porto, Portugal.
Pancreatic cancer (PC) is the sixth leading cause of cancer-related deaths worldwide, primarily due to late-stage diagnosis and limited treatment options. While novel biomarkers and immunotherapies are promising, further research into specific molecular targets is needed. Glycans, which are carbohydrate structures mainly found on cell surfaces, play crucial roles in health and disease.
View Article and Find Full Text PDFMOTAI: A Novel Method for the Study of O-GalNAcylation and Complex O-Glycosylation in Cancer.
Anal Chem
July 2024
Center for Clinical Mass Spectrometry, College of Pharmaceutical Sciences, Soochow University, Jiangsu, 215123, China.
Article Synopsis
- The Tn antigen is a potential cancer biomarker linked to immature O-glycosylation, but analyzing its variations has been challenging due to a lack of reliable methods.
- Researchers developed a new method called MOTAI for sequentially analyzing different O-glycosylation types using various enzymes, enhancing the study of O-GalNAcylation.
- By applying MOTAI, the study identified numerous glycoproteins that are elevated in colorectal cancer tissues, suggesting their involvement in tumor development and providing insights for future cancer diagnostics.
Siglec-6 as a therapeutic target for cell migration and adhesion in chronic lymphocytic leukemia.
Nat Commun
June 2024
Comprehensive Cancer Center, The Ohio State University, Columbus, OH, USA.
Siglec-6 is a lectin receptor with restricted expression in the placenta, mast cells and memory B-cells. Although Siglec-6 is expressed in patients with chronic lymphocytic leukemia (CLL), its pathophysiological role has not been elucidated. We describe here a role for Siglec-6 in migration and adhesion of CLL B cells to CLL- bone marrow stromal cells (BMSCs) in vitro and compromised migration to bone marrow and spleen in vivo.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!